Regeneron Tops Revenue Estimates at $5.1 Billion as Sanofi Collaboration Revenue Rises 68%
Regeneron updated its 2026 guidance, raising non-GAAP R&D to $6.05 billion to $6.15 billion and lowering non-GAAP SG&A to $2.40 billion to $2.50 billion.
Regeneron Pharmaceuticals REGN
Regeneron Pharmaceuticals, Inc. · Nasdaq · Pharmaceutical Preparations
$818.77+0.68%close on Oct. 29, 2026 · volume 782K · Yahoo Finance
Price, last 48 sessions
Our coverage
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 14, 2026 | Andrew J. Murphy Co-Chief Scientific Officer | Sold 10b5-1 plan | 4,147 | $772.70 $753.76-$781.47 | $3.20 million |
| Sept. 3, 2026 | Marion McCourt EVP Commercial | Sold 10b5-1 plan | 1,131 | $857.39 | $969,708 |
| Sept. 2, 2026 | Marion McCourt EVP Commercial | Sold 10b5-1 plan | 1,215 | $850.00 | $1.03 million |
| Sept. 2, 2026 | Kathryn Guarini director | Sold 10b5-1 plan | 400 | $850.00 | $340,000 |
| Aug. 10, 2026 | Kathryn Guarini director | Sold 10b5-1 plan | 400 | $800.00 | $320,000 |
| Aug. 10, 2026 | Huda Y. Zoghbi director | Sold 10b5-1 plan | 800 | $800.00 | $640,000 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedRegeneron Q3 2026 non-GAAP EPS of $20.07 beats $16.25 consensus as revenue rises 36% to $5.1 billion; Sanofi expansion adds $1.0 billion up-front for Q4
Entry into a material definitive agreement · Results of operations and financial condition · Other events
Departure/appointment of directors or officers · Financial statements and exhibits